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cases	 of	 placenta	 accreta	 presenting	with	 “the	 abnormal	 adherence	
of	the	afterbirth	 in	whole	or	 in	parts	to	the	underlying	uterine	wall.”	
































maternal	 deaths	 due	 to	 its	 complications.6	Thus,	 it	 is	 not	 surprising	
that	80	years	later,	more	than	90%	of	women	presenting	with	a	pla-
centa	accreta	have	had	at	least	one	prior	cesarean	delivery.5–9
PAS	 disorders	were	 first	 defined	 by	 Luke	 et	al.3	 to	 include	 both	
abnormally	adherent	and	invasive	placentas.	Three	categories	are	now	
considered:	 (1)	 adherent	placenta	accreta,	 also	described	by	pathol-







involved.	Finally,	 the	degree	of	villous	adhesion	or	 invasion	 is	 rarely	
uniform	throughout	the	placenta,	limiting	the	accuracy	of	microscopic	
diagnosis	 when	 the	 whole	 uteroplacental	 interface	 is	 not	 available	
for	analysis.3	This	 terminology	describes	accurately	 the	 spectrum	of	
accreta	placentation;	however,	an	increasing	number	of	clinicians	have	
started	using	an	archaic	“Victorian”	etymology,	i.e.	“morbidly	adherent	
placenta”	 (MAP),	 to	describe	 the	different	grades	of	accreta	placen-
tation.	This	is	confusing	and	misleading,	as	technically	it	excludes	the	
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invasive	forms	of	PAS	disorders.	Other	terms	used	include	“placental	




It	 is	 essential	 to	 evaluate	 epidemiological	 data	 and	 outcome	
based	 on	 clear	 diagnostic	 criteria	 and	 this	 is	 only	 possible	 if	 the	
same	 starting	 points	 are	 used.	 It	would	 be	 considered	 inadequate	
if	an	invasive	tumor	of	the	uterine	cervix	or	any	other	organs,	such	
as	 the	 liver,	was	encumbered	with	a	 similar	plethora	of	 inaccurate	
terminology.	 Therefore,	 when	 evaluating	 accreta	 placentation	 to	
obtain	accurate	epidemiologic	data	there	is	a	need	for	a	standardized	
approach.	The	term	PAS	disorders	proposed	by	Luke	et	al.3	provides	






There	 is	 increasing	 evidence	 that	 the	 management	 of	women	






techniques	 have	played	 an	 increasing	 role	 in	 the	prenatal	 diagno-
sis	of	this	condition,	facilitating	prenatal	management	and	allowing	
programmed	delivery	tailored	for	the	individual	need	of	the	patient	
in	 the	 adequate	 environment.14	 Ultrasound	 imaging	 is	 the	 most	
commonly	 used	 technique	 to	 diagnose	 PAS	 disorders	 prenatally.	
However,	 the	terminology	employed	to	describe	the	different	cat-
egories	of	 ultrasound	 signs	was	 also	heterogeneous	 and	 complex.	

























nosis	 and	 management	 of	 PAS	 disorders.	 The	American	 College	 of	
Obstetricians	 and	 Gynecologists	 (ACOG)	 and	 the	 Royal	 College	 of	
Obstetricians	and	Gynaecologists	 (RCOG)	have	published	guidelines	
with	 evidence-	based	approaches	 for	optimized	 clinical	management	
of	PAS	disorders.22,23	However,	these	guidelines	are	designed	for	the	
specific	 needs	 of	 local	 healthcare	 environments.	 Again	 the	 success	
rate	and	outcome	of	each	procedure	 is	directly	 linked	to	the	degree	
of	placental	 invasiveness	 in	depth	and	 laterally.	Thus	 the	evaluation	
of	the	efficacy	and	safety	of	a	management	method	depends	on	the	




















After	 the	 three-	round	 process	 was	 complete,	 the	 members	 of	 the	
panel	were	asked	to	read	the	final	version	and	provide	written	consent	
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